798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1819122358825254912 |
|---|---|
| author | Aaron Scott Manish Patel Julie Bauman Jeffrey Clarke Howard Burris Justin Gainor Martin Gutierrez Daniel Cho Ricklie Julian Pamela Cohen Joshua Frederick Celine Robert-Tissot Honghong Zhou Kinjal Mody Karen Keating Robert Meehan |
| author_facet | Aaron Scott Manish Patel Julie Bauman Jeffrey Clarke Howard Burris Justin Gainor Martin Gutierrez Daniel Cho Ricklie Julian Pamela Cohen Joshua Frederick Celine Robert-Tissot Honghong Zhou Kinjal Mody Karen Keating Robert Meehan |
| author_sort | Aaron Scott |
| collection | DOAJ |
| first_indexed | 2024-12-22T06:51:11Z |
| format | Article |
| id | doaj.art-c629be3a7f774c30a5a88a7f86a82a58 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-22T06:51:11Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-c629be3a7f774c30a5a88a7f86a82a582022-12-21T18:35:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0798798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an updateAaron Scott0Manish Patel1Julie Bauman2Jeffrey Clarke3Howard Burris4Justin Gainor5Martin Gutierrez6Daniel Cho7Ricklie Julian8Pamela Cohen9Joshua Frederick10Celine Robert-Tissot11Honghong Zhou12Kinjal Mody13Karen Keating14Robert Meehan151University of Arizona, Tuscon, AZ, USA6Florida Cancer Specialists, Sarasota, FL, USA1University of Arizona, Tuscon, AZ, USA3Duke, Durham, NC, USA2SCRI, Nashville, TN, USA8Mass General Hospital, Boston, MA, USA3Hackensack University Medical Center, Hackensack, NJ, USA11NYU Medical Oncology Associates, New York, NY, USA1University of Arizona, Tuscon, AZ, USA7Moderna, Tenafly, NJ, USA7Moderna, Tenafly, NJ, USA7Moderna, Tenafly, NJ, USA7Moderna, Tenafly, NJ, USA7Moderna, Tenafly, NJ, USA7Moderna, Tenafly, NJ, USA7Moderna, Tenafly, NJ, USA |
| spellingShingle | Aaron Scott Manish Patel Julie Bauman Jeffrey Clarke Howard Burris Justin Gainor Martin Gutierrez Daniel Cho Ricklie Julian Pamela Cohen Joshua Frederick Celine Robert-Tissot Honghong Zhou Kinjal Mody Karen Keating Robert Meehan 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update Journal for ImmunoTherapy of Cancer |
| title | 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update |
| title_full | 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update |
| title_fullStr | 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update |
| title_full_unstemmed | 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update |
| title_short | 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update |
| title_sort | 798 safety tolerability and immunogenicity of mrna 4157 in combination with pembrolizumab in subjects with unresectable solid tumors keynote 603 an update |
| work_keys_str_mv | AT aaronscott 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT manishpatel 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT juliebauman 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT jeffreyclarke 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT howardburris 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT justingainor 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT martingutierrez 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT danielcho 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT rickliejulian 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT pamelacohen 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT joshuafrederick 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT celineroberttissot 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT honghongzhou 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT kinjalmody 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT karenkeating 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate AT robertmeehan 798safetytolerabilityandimmunogenicityofmrna4157incombinationwithpembrolizumabinsubjectswithunresectablesolidtumorskeynote603anupdate |